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Abstract
Purpose Cancer treatments often produce undesirable side-effects, such as skin toxicity, impacting on everyday functioning 
and health-related quality of life (HRQoL). This experimental study sought to determine whether aesthetic products and treat-
ments could significantly decrease perceived skin symptoms, psychological distress and improve skin-related QoL (SRQoL).
Methods An experimental group composed of 100 breast patients was enrolled for specialized aesthetic treatments at the 
European Institute of Oncology (IEO) and compared to a control group of 70 breast patients who did not receive any aes-
thetic treatment. A measure of SRQoL (i.e., Skindex-16) and a distress thermometer were administered longitudinally at 
three time points: at baseline (T0), at 7 days from beginning of aesthetic treatment (T1) and at 28 days from beginning of 
aesthetic treatment (T2).
Results Results demonstrated the efficacy of aesthetic treatment in reducing distress and improving SRQoL: while the 
experimental group showed significant improvements in all HRQoL areas, the control group worsened. Specifically, at T1 
and T2 there were significant improvements on distress and Skindex subscales in the experimental group, with an almost 
complete remission of perceived symptoms at T2. Moreover, all reported cutaneous reactions significantly improved after 
the specialized treatments, with no differences in SRQoL in skin reaction type.
Conclusions These findings demonstrate that aesthetic treatments for side-effects of cancer therapies can alleviate perceived 
distress and improve skin symptoms and HRQoL.
Keywords Skin toxicity · Aesthetic treatment · Cancer treatments · Quality of life · Health psychology
Introduction
Invasive breast cancer is often treated with mastectomy or 
conservative surgery combined with radiotherapy (RT) or 
other cancer treatments, such as cytotoxic chemotherapy 
(CC) and targeted therapy (TT), depending on the nature 
and kind of breast cancer [1]. Side-effects of oncological 
therapies which are often overlooked are skin toxicity and 
skin-related disorders. Physicians tend to focus on treatment 
outcome and toxicity risk, failing to recognize the skin dis-
tress reported by the patient and creating a gap between 
patient’s perceived symptoms and those assessed by the 
physician [2]. Women receiving cancer therapy may expe-
rience skin-related side-effects that negatively affect not only 
adherence to therapy but even health-related quality of life 
(HRQoL) [3, 4]. For these reasons, preventing and manag-
ing skin reactions are becoming increasingly important to 
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promote compliance with treatment, comfort and patient’s 
well-being [5–7].
The majority of the skin changes take several weeks from 
completion of therapy to heal [2]. For this reason, healing 
from skin-related disorders can be perceived as a relent-
less process due to worsening discomfort and increased 
skin changes [8]. For radiotherapy treatment, the first skin 
reactions appear within 1 to 4 weeks from the beginning of 
treatment, and the most unpleasant effects are those linked 
to tactile and nociceptive effects, such as pain, skin color 
and texture changes [9]. Chemotherapy can cause swelling, 
nail damage, and hand-foot syndrome, all of which impact 
on hand and feet functioning [10, 11]. Skin toxicity is also 
one of the main collateral effects of TT [12]. Although most 
patients report mild to moderate skin-related disorders, the 
level of distress and the impact on HRQoL is perceived as 
moderately high [2].
Overall, pain and skin-related disorders can be difficult 
to bear due to the visibility of skin changes and impact on 
day-to-day functioning. For these reasons, it is advisable to 
recommend the use of skin care products, such as aqueous 
creams, aloe vera, hyaluronic acid, which can improve self-
image and subsequently decrease anxiety [13–19].
Although evidence regarding the efficacy for various 
products in the treatment of skin-related disorders is con-
flicting [16, 20], an important aspect of patient’s wellbeing, 
namely skin related QoL (SRQoL), is often neglected in the 
literature. Previous studies have investigated the effective-
ness of aesthetic treatments in improving fatigue, anxiety, 
depression and sleep disturbances in various types of can-
cer at different stages [21–26]. However, SRQoL has rarely 
been introduced in previous studies; even if guidelines indi-
cate that it should be incorporated to evaluate the efficacy 
of skin reaction management [14]. Schnur and colleagues 
[9] investigated SRQoL in women with stage 0–III breast 
cancer undergoing RT and noticed that women experienced 
emotional distress, physical discomfort, and body image dis-
turbance. Changes in skin color increased anxiety, concern 
about others reactions and changes in their day-to-day func-
tioning (e.g., changing bras and clothing). These changes 
impact emotionally on the patient’s perception of their body, 
as it gives a visible effect to cancer [27].
Summarizing, dermatological effects of cancer treat-
ments have a negative impact on SRQoL through increased 
distress, withdrawal from relationships and increased risk 
of mood disturbances and non-adherence to treatment. The 
overall aim of the following study was to assess the efficacy 
of aesthetic treatments in promoting women’s perceived 
SRQoL. We hypothesize that aesthetic treatments performed 
by a specialized cosmetologist could significantly improve 
skin symptoms, patient’s psychological state and daily func-
tioning reducing the negative impact of skin lesions on their 
HRQoL during cancer treatment.
Materials and methods
Participants
Participants in this study were breast cancer patients receiv-
ing CT, TT or radiotherapy at the European Institute of 
Oncology (IEO) between April 2016 and August 2017. 
A total of 100 patients were enrolled in the experimental 
group, with one drop-out and a total number of 99 partici-
pants included. Seventy patients were enrolled in the control 
group, with one drop-out and a total number of 69 partici-
pants included.
Sampling procedure
Recruitment was performed by the oncologists specialized in 
dermatology or day hospital nurses working in the Derma-
tology Unit based on the characteristics of the skin injuries 
and compliance to therapy. Subjects who agreed to partici-
pate were assessed at the initial visit for adverse skin reac-
tions and graded based on the NCI-CTCAEv3.0 (National 
Cancer Institute-Common Terminology Criteria for Adverse 
Events) [28] or RTOG/EORTC (Radiation Therapy Oncol-
ogy Group/European Organization for Research and Treat-
ment of Cancer) Radiation Toxicity Grading [29]. Only 
patients with grade I adverse skin reaction were selected 
to participate in this study. Patients who asked for aesthetic 
treatments were enrolled within the experimental group and 
referred to the Dermophisiologique Oncology Aesthetic 
Center for APEO dermatological treatments (Professional 
Association of Oncological Aesthetics). Patients who did 
not ask for a professional aesthetic treatment were enrolled 
in the control group. The experimental group filled in the 
questionnaires during their visit to the Dermophisiologique 
Oncology Aesthetic Center, whereas the control group 
filled in the questionnaires soon after the medical visit for 
adverse skin reactions at T0 and was contacted via phone by 
APEO cosmetologists to complete their follow-up (T1 and 
T2). Higher grades of adverse skin reactions to therapies 
require medical intervention and were therefore excluded 
from enrollment (see Table 1 for a detailed description of 
inclusion and exclusion criteria).
After 28 days from recruitment, the referring oncologists 
specialized in dermatology conducted a second evaluation 
on skin reactions to cancer treatments based on the NCI-
CTCAEv3.0 or RTOG/EORTC scales.
Sample size calculation
A sample size calculation was conducted using a repeated 
measure analysis of variance (ANOVA) within-between 
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interaction (i.e., experimental vs. control group and time) 
approach with G*Power 3 statistical software with 5% of 
significance level, 80% of power, a weak correlation between 
measures of 0.3 and weak-medium effect size of 0.20. 
Because the assumption of sphericity may be unmet in our 
data, the required sample size was computed by applying a 
correction for a potential significant deviation from spheric-
ity (ε = 0.5) [30]. This calculation showed that a total sample 
size of 94 was sufficient to detect a significant interaction 
effect between groups and time. This sample size is also suf-
ficient to detect a significant main effect of intervention vs. 
control group (minimum required sample size = 108) and the 
significant main effect of time (minimum required sample 
size = 94).
Measures
Patients of both experimental and control groups were 
administered the Skindex-16 scale [31] and the distress 
thermometer [32] at three time points: at recruitment (T0), 
after 1 week (T1), and after 28 days (T2) from enrollment.
The Skindex-16 is a 16-item self-report instrument that 
measures the effects of skin disease on HRQoL comprehen-
sively. At the beginning of the questionnaire, the following 
statement is presented: “During the past week, how often 
have you been bothered by..”. Each question asks subjects 
to rate on a 7-point Likert scale (ranging from 0 “Never 
bothered” to 6 “Always bothered”) the level of concern or 
discomfort due to their specific skin condition (e.g., itching, 
burning, frustration about skin condition). It is composed of 
three subscales: perceived symptoms (items 1–5), emotions 
(items 6–11), and daily functions (items 12–16). Responses 
to each item were transformed into a linear scale of 100, 
varying from 0 (never bothered) to 100 (corresponding to 
6, always bothered) [31]. Each raw score was then normal-
ized for the statistical analysis. The final score is the aver-
age of the patient’s responses in a given domain (perceived 
symptoms, emotions, and daily functions). Higher scores 
indicate higher levels of discomfort or concern. This 
questionnaire is considered internally reliable (Cronbach 
α = 0.86–0.93) and has adequate test–retest reliability, con-
struct, and content validity [33].
The distress thermometer is a one-item self-report screen-
ing tool, with a visual analogue scale ranging from 0 (no dis-
tress) to 10 (extreme distress) and a midpoint anchor labeled 
“moderate distress”, which is used to measure the level of 
psychological distress patients have experienced over the 
past week, including the day of screening completion. Cutoff 
scores have been validated and are considered of clinical 
utility in medical settings; moreover, overall scores have 
been compared to other well-known measures (i.e., Hospital 
Anxiety Depression Scale) to test construct validity [34, 35].
Intervention
The experimental group received a 1-h session of specific 
aesthetics treatments protocols twice a week, by a qualified 
cosmetologist. The APEO cosmetologist is a professional 
dedicated to treatments that protect the skin from toxicity, 
solving blemishes, soothing and irritations due to cancer 
therapies. The APEO cosmetologists undergo a very rigid 
and certified training during which they acquire the scientific 
expertise to understand what cancer pathologies and thera-
pies are, and how they act at the cutaneous level. The Profes-
sional Association of Oncological Aesthetics, in collabora-
tion with oncologists, cancer researchers, plastic surgeons, 
and specialized cosmetologists lecturers, provides 120 h of 
training for qualified cosmetologists (3 years of professional 
school degree). Theoretical teaching is supported by a prac-
tical stage during which cosmetologists learn the protocols 
to be implemented based on cancer treatments skin toxic-
ity and skin symptoms. They furthermore learn techniques 
of pedicure, manicure, and massage, specific for patients 
Table 1  Inclusion and exclusion criteria for study enrollment
Inclusion criteria
 Diagnosis of breast cancer histologically confirmed
 Subjects treated with chemotherapeutic agents, targeted therapy or radiotherapy with skin side-effects
 Subjects with grade I of adverse skin symptoms
 Female subjects 18 of age
 Conditions favoring the correct execution of the proposed program
 Signature of informed consent
Exclusion criteria
 Other cancer diagnosis
 Pregnancy or breastfeeding in progress
 Subjects with adverse skin symptoms higher than grade I
 Psychic or other disorders
 Subjects with skin diseases, ulcers, dyschromia that can alter the accuracy of preexisting assessment or other skin conditions that do not allow 
application of the cosmetic product
 Known hypersensitivity or allergy to one of the components of the products
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undergoing cancer therapy. After a final examination, the 
acquired competences on cancer aesthetic protocols are 
certified.
For this study, aesthetic treatments and cosmetic prod-
ucts were specifically created for skin care treatments during 
breast cancer therapies and provided by APEO cosmetolo-
gists. At T0, all patients’ lesions were evaluated, and specific 
cosmetic treatment protocols were applied (Fig. 1).
The type of aesthetic treatments is summarized in Supple-
mentary Material 1, while treatment products composition 
(Ontherapy® by Dermophisiologique) and their properties 
are described in detail in Supplementary Material 2.
At T1, the patient underwent a second checkup with the 
APEO cosmetologist, for a second evaluation and a focused 
treatment. The same treatment was then applied at T2. 
Between T0, T1, and T2, the patient was instructed to apply 
specific cosmetic products daily, for cleansing, hydration, 
nourishment, and protection of their skin.
Cosmetic products and treatments provided by APEO 
cosmetologists have been endorsed by oncology physicians 
(the first oncological activities of the APEO were at the Der-
mophisiologique Oncology Aesthetic Center opened in the 
European Institute of Oncology IEO with the consent of 
prof. Umberto Veronesi, see https ://www.onthe rapy.it for 
more info about certifications), and the involvement of a 
medical professional was important for this study to ensure 
an objective medical evaluation of patients’ dermatological 
symptoms. APEO cosmetologist has certified competen-
cies in evaluating the impact of grade I skin symptoms on 
patient’s HRQoL and can decide for appropriate personal-
ized aesthetic protocols without the support/coordination of 
the oncology professional (that instead is required in case of 
higher adverse skin events). Nevertheless, aesthetic proto-
cols are not part of standard medical care, and patients are 
free to use (or not) the Dermophisiologique products and 
the dermatological treatments object of the study without 
a medical supervision. All patients included in this study 
claimed to have correctly applied the cosmetic products. The 
simultaneous application of other cosmetics was strongly 
discouraged.
Statistical analysis
Mixed analyses of covariance (ANCOVAs) were performed 
to evaluate the differences between experimental and control 
groups in the trend of Skindex total score (SRQoL), Skin-
dex subscales and distress by verifying the interaction effect 
between time and presence/absence of aesthetic treatment. 
Because the control and the intervention groups differed at 
baseline in hand-foot syndrome and nail damage, these two 
variables were introduced as covariates in all these analyses. 
Furthermore, in the experimental group only, we applied 
Fig. 1  Cancer treatments, dermatological side-effects, corresponding wellness, and cosmetic treatments (*)
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a mixed ANOVA to verify the efficacy of APEO aesthetic 
treatments on SRQoL subscales and distress considering 
the different groups of cancer treatment patients (CC, TT, 
radiotherapy) by checking for the interaction effect between 
time and cancer treatment typologies. We performed post 
hoc comparisons by using the Bonferroni correction for 
multiple comparisons when significant results were obtained 
(p < 0.05).
At each time point, independent T tests were performed 
to verify significant differences in SRQoL total score and 
distress among patients in the experimental group based on 
the presence/absence of each specific dermatological side-
effects (nail damage vs. no nail damage, hand-foot syndrome 
vs. no hand-foot syndrome, xerosis vs. no xerosis, etc.). We 
could not use ANOVA in this case since each patient usually 
had more than one dermatological side-effect due to cancer 
treatment.
All the analyses were performed with SPSS statistical 
software version 23.0.
Results
Demographic characteristics, percentages of cancer treat-
ments, clinical conditions, and dermatological side-effects 
at baseline are described in Table 2.
The mixed ANCOVA revealed that there was a significant 
interaction between time and presence/absence of aesthetics 
treatments on distress levels (F2,290 = 80.75; p < 0.001), with 
an opposite trend between the experimental and the control 
group (see Fig. 2a). Post hoc comparison with Bonferroni 
correction showed a constant decrease in distress in the 
experimental group and a constant increase in the control 
group. At T0, the experimental group was more distressed 
than patients in the control group, whereas at T2 the control 
group showed higher distress than women who underwent 
aesthetic treatments. The two groups did not differ in distress 
scores at T1.
With regard to the Skindex-16 total score (an overall 
mean score of SRQoL), results showed again an opposite 
trend for the experimental and the control group, with a 
significant interaction between time and presence/absence 
of aesthetics treatments (F2,330 = 210.42; p < 0.001) (see 
Fig. 2b). Post hoc comparison with Bonferroni correction 
showed constant improvement of SRQoL in the experimen-
tal group and constant worsening of SRQoL in the control 
group. At T0, the experimental group reported a worse 
SRQoL due to dermatological side effect, compared to 
the control group, whereas at T1 and T2 the control group 
showed higher scores at Skindex, thus reporting a decrease 
in SRQoL.
We then investigated whether there were differences 
between the experimental and control groups in the trends of 
the three subscales of the Skindex-16 (i.e., perceived symp-
toms, emotions, and functioning).
Results showed that the experimental group and the con-
trol group differed in trend of perceived symptoms (F2,330 = 
211.03; p < 0.01), emotions (F2,330 = 160.89; p < 0.01), and 
functioning (F2,330 = 109.02; p < 0.01).
Post hoc comparison with Bonferroni correction high-
lighted the significant improvement in the three subscales of 
Skindex in the experimental group and a constant worsening 
Table 2  Socio-demographic characteristics of the sample, patients’ cancer treatments, and dermatological side-effects
SD standard deviation
*p < 0.05; **p < 0.01; N = number
a t test; b Chi2
Variables Experimental group Control group Statistic
N = 99 N = 99
Mean age (SD) 51.5 (10.8) 54.2 (12.0) 1.62a
Cancer treatments N % N %
 Cytotoxic chemo-
therapy
36 36.4 31 44.3 1.28b
 Targeted therapy 31 31.3 21 30.0
 Radiotherapy 32 32.3 18 25.7
Cutaneous reactions  N % N %
 Hand-foot syndrome 37 37.4 16 22.9 4.01b*
 Radiodermatitis 32 32.3 18 25.7 0.86b
 Edema 31 31.3 14 20.0 2.68b
 Xerosis 25 25.3 19 27.1 0.08b
 Nail damage 14 14.1 27 38.6 13.31b**
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in the control group. The experimental group reported worse 
perceived symptoms at T0, with a higher mean score in the 
Skindex subscale compared to the control group, and marked 
improvements at T1 and T2, compared to control group 
scores. Emotions and functioning scores were significantly 
higher for the experimental group at T0, similar to the con-
trol group at T1 and significantly lower at T2 compared to 
the control group. Mean scores of Skindex subscales in the 
experimental and control group across time are reported in 
Table 3.
Fig. 2  a Interaction between 
time and aesthetic treatment 
effects on distress levels in the 
experimental and control group; 
b interaction between time and 
aesthetic treatment effects on 
overall SRQoL in the experi-
mental and control group. Mean 
scores of distress thermometer 
and Skindex-16 scale at T0, 
T1, and T2 are reported in the 
diagram labels
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We explored possible differences in Skindex subscales 
among patients in the experimental group, based on the dif-
ferent cancer treatments (CC, TT, radiotherapy) they were 
undergoing. Outcomes showed that there was no significant 
difference among groups in perceived dermatological symp-
toms (F4,192 = 1.282; p > 0.05), with a similar trend during 
the period of their aesthetic treatment. They all had a sig-
nificant improvement in perceived symptoms, with a clear 
reduction in the same after 28 days of aesthetic treatments 
(Fig. 3). Post hoc comparison with Bonferroni correction 
showed no differences among groups at T0, T1, and T2.
The same results emerged for the Emotion subscale 
(F4,192 = 0.78; p > 0.05), and post hoc showed no differences 
among groups at different time points.
Data showed no significant interaction between time and 
cancer treatment on functioning (F4,192 = 1.88; p > 0.05), 
showing that all the cancer treatment groups had an equal 
improvement in functioning after 1 week and at 28-day 
follow-up. Post hoc comparison with Bonferroni correction 
showed that patients who underwent TT were significantly 
more compromised in their functioning compared to patients 
who underwent radiotherapy at T0 and T1 (Fig. 4).
Results showed no significant differences in distress 
trends between patients undergoing CC, TT, and radiother-
apy (F4,186 = 0.39; p > 0.05). Post hoc comparison showed 
all cancer treatment groups had comparable distress levels 
at each time point and all groups significantly improved over 
time.
Finally, a significant improvement in perceived SRQoL 
was registered for all cutaneous reactions to cancer treat-
ments (Hand-foot syndrome, Radiodermatitis, Edema, etc.) 
after APEO aesthetic intervention. Differences emerged 
among patients with the hand-foot syndrome at T0, who 
had worse SRQoL than the group without this side-effect, 
and radiodermatitis at T1 and T2 (Table 4), who perceived 
less suffering than people with other cutaneous reactions to 
cancer treatments.
No significant differences emerged among patients in 
distress levels at T0, T1, and T2 based on dermatological 
symptoms.
The subjective evaluation of the patients in the experi-
mental group, detected with the Skindex-16 scale and the 
Table 3  Skindex-16 subscales and distress mean scores in the experi-
mental and control groups, at T0, T1 e T2
EG experimental group, CG control group, SD standard deviation
Subscale T0 enrollment T1 after 7 days T2 after 28 days
Mean (SD) Mean (SD) Mean (SD)
Symptoms EG 54.0 (25.7) 32.6 (20.4) 12.7 (13.5)
Symptoms CG 30.9 (26.1) 44.0 (23.2) 61.4 (25.5)
Emotions EG 54.6 (27.4) 35.1 (22.7) 15.2 (14.6)
Emotions CG 26.3 (30.1) 38.0 (26.8.0) 52.2 (28.6)
Functions EG 34.3 (26.7) 22.6 (21.0) 10.4 (13.7)
Functions CG 17.9 (26.3) 27.8 (24.9) 41.7 (29.3)
Fig. 3  Interaction between 
time and aesthetic treatment 
effects on perceived symptoms 
in different cancer treatments 
groups. Mean scores of Skindex 
symptoms subscale at T0, T1, 
and T2 are reported in the 
diagram labels
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Distress Thermometer, corresponded to a reduction in the 
level of symptoms and an improvement in functioning 
reported on the NCI-CTCAEv3.0 scale by the referring 
oncologist. In particular, patients who had the hand-foot 
syndrome, with difficulty in wearing shoes at T0, showed 
a reduction in rash and hyperkeratosis and had an enhance-
ment in walking at T2. Patients with xerosis, who reported 
intense itching and initial break in the skin at T0, showed 
a reduction in desquamation and tingling at the end of the 
dermatological treatment.
Patients who were subjected to nail changes such as 
ridges (koilonychia), nail pitting, and erythema of the peri-
onychium, due to cancer treatments, had difficulties in carry-
ing out their daily activities at T0. They showed an improve-
ment in the elasticity and compactness of the nail plate and a 
consistent reduction in erythema of the perionychium at T2.
Finally, patients who underwent radiotherapy and had 
grade 1 lesions evaluated with the RTOG / EORTC scale 
at T0, such as rash, itching, and initial skin atrophy, showed 
a reduction in erythema and itching and a blockage of the 
Fig. 4  Interaction between time 
and aesthetic treatment effects 
on functioning in different 
cancer treatments groups. Mean 
scores of Skindex Functioning 
subscale at T0, T1, and T2 are 
reported in the diagram labels
Table 4  Mean differences 
in Skindex-16 total scores 
(QoL) among patients with/
without specific dermatological 
symptoms
SD standard deviation, H-f hand-foot; Y yes; N no
*p < 0.06
Side-effects N T0 t T1 t T2 t
Mean (SD) Mean (SD) Mean (SD)
H-f syndrome Y 37 53.2 (21.3) 1.9* 34.1 (17.0) 1.7 13.7 (12.2) 0.6
H-f syndrome N 62 44.3 (21.3) 27.7 (17.1) 12.2 (11.7)
Radioderm Y 32 41.2 (21.5) − 2.1* 24.2 (14.9) − 2.4* 10.5 (9.7) − 1.3
Radioderm N 67 50.7 (21.2) 32.9 (17.7) 13.8 (12.6)
Edema Y 31 52.9 (21.7) 1.6 33.6 (18.5) 1.4 12.5 (12.6) − 0.1
Edema N 68 45.2 (21.4) 28.5 (16.6) 12.8 (11.6)
Xerosis Y 25 47.8 (23.3) 0.4 31.5 (19.8) 0.5 16.2 (16.4) 1.7
Xerosis N 74 47.6 (21.2) 29.6 (16.4) 11.6 (9.7)
Nail damage Y 14 42.6 (17.9) 0.9 27.3 (15.1) 0.6 9.4 (8.9) 1.1
Nail damage N 85 48.5 (22.2) 30.5 (17.6) 13.3 (12.2)
Quality of Life Research 
1 3
progression of skin atrophy at the end of the dermatological 
treatment (T2).
Discussion
As highlighted previously, most of the available therapies 
are associated with side-effects that impact significantly on 
the patient’s HRQoL [36, 37]. Various studies reported that 
HRQoL during therapies decreases and that incidence of 
reported symptoms (e.g., fatigue, mood disturbances, skin, 
and sensation changes) increases [38–40]. Our data are in 
line with these studies, suggesting that patients’ evaluation 
of their HRQoL should always be taken into account and 
monitored during cancer treatments. Supportive cares, which 
focus on patients’ reported symptoms that are not measur-
able with laboratory tests or imaging procedures, may have 
a beneficial effect on overall patients’ well-being and adher-
ence to cancer treatments.
The main evidence of the present study is that special-
ized APEO aesthetic treatments, conducted with specific 
cosmetic products (Ontherapy® by Dermophisiologique), 
are efficient in managing the impact that side-effects of 
CC, TT, and radiotherapy have on patients’ SRQoL and 
distress. Improvements in dermatological symptoms and 
functioning were also confirmed during the medical evalu-
ation performed by the referring oncologists specialized in 
dermatology.
The APEO aesthetic treatments promote women’s psy-
chological well-being and HRQoL, resulting in a clear 
reduction in perceived dermatological symptoms and an 
increase in positive emotions related to self-perception and 
relationship with others. In our samples, patients who asked 
for specialized aesthetic treatment and were enrolled in the 
experimental group perceived more accentuated dermato-
logical symptoms compared to the control sample.
Even if dermatological side-effects caused psychologi-
cal suffering, distress, and worse functioning in the experi-
mental group, a week after the beginning of the aesthetic 
treatments significant improvements were registered in all 
domains of SRQoL and distress, with an almost complete 
healing of perceived skin symptoms, negative emotions, and 
negative functioning after 28 days of aesthetic treatments. In 
contrast, patients in the control group had significantly lower 
scores in all domains of SRQoL and their distress levels 
raised markedly, manifesting medium to high pain at 28 days 
follow-up. Other studies have reported advantages in apply-
ing cosmetic products on skin reactions due to oncological 
therapies [13, 14, 17], whereas Quintard and Lakdja [41] 
described the benefits of beauty treatments on psychological 
distress, body image and coping in breast cancer patients. 
Despite this evidence, currently, there are no standardized, 
recommended onco-aesthetics protocols to counteract the 
impact of cancer treatments’ side-effects on SRQoL.
Consistent with previous literature [42–44], cytotoxic 
chemotherapy and targeted therapies turned out to have a 
worse impact on daily functioning compared to radiotherapy 
in our experimental group. Despite this initial discrepancy, 
no significant differences emerged between oncological 
therapies in any of SRQoL domains after 28 days of special-
ized aesthetic treatments; rather all patients benefited equally 
from APEO treatments. Results confirm the effectiveness 
and importance of suggesting aesthetic treatment to patients 
undergoing different kinds of breast cancer treatments, as 
this can promote cancer patients’ well-being and HRQoL 
before, during, and after treatments and reduce distress. In 
our study, women who had radiodermatitis perceived them-
selves as being overall less compromised in their HRQoL, 
while patients with hand-foot syndrome considered them-
selves as highly affected by their dermatological condition 
before starting APEO treatments. This result confirms past 
literature, which highlighted that hand-foot syndrome is the 
symptom which brings more distress, suffering, and discon-
tinuation of therapy due to a marked decrease in patient’s 
HRQOL [45].
Some limitations of the current study should be men-
tioned. First, the control group is smaller than the experi-
mental group. Moreover, patients were not randomly 
assigned to the experimental or the control group, as we 
included in the experimental group all patients that asked for 
specialized aesthetic treatment. As a consequence, the two 
groups differed at T0 regarding their SRQoL and distress 
levels, with patients in the experimental group reporting 
more concern and discomfort about their skin conditions. 
However, this initial difference between experimental and 
control group did not influence results about SRQoL and 
distress trends across time. Further studies should replicate 
these findings with bigger samples and with diverse tumor 
diagnosis in randomized controlled trials, in order to pro-
mote the development of guidelines. Furthermore, the type 
of treated symptoms often overlapped. Thus, a comparison 
between specific symptoms groups was not possible: future 
research could investigate whether specific skin lesions are 
associated with worse SRQoL and psychological well-being.
Conclusion
The efficacy of specialized aesthetic treatments on perceived 
distress and skin-related problems, highlighted in this study, 
demonstrates that they can become complementary therapies 
for cancer management. It is important to include psycho-
logical measures in studies assessing these skin injuries, as 
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they often impact on their daily functioning and HRQoL. 
An integrative approach between oncology, psychology, and 
aesthetic skin management is strongly advised in order to 
offer the best comprehensive care to patients.
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